SUBSCRIBE
SUBSCRIBE

BridgeBio LLC

NEWS
Biotech Bay
BioPharm Executive: Money Talk
Venture capital is hopping, attracted to some of the past several years’ successes.
October 14, 2017
 · 
1 min read
 · 
Karl Thiel
3 Biotechs That Could be Taken Out This Quarter
Business
Bay Area Startup BridgeBio Quietly Snags $135 Million From a Bunch of Wall Street Firms
September 13, 2017
 · 
2 min read
3 Biotechs That Could be Taken Out This Quarter
Business
Another Biotech is Born as Bay Area’s BridgeBio Pharma Launches Eidos Therapeutics With $27 Million
April 27, 2017
 · 
2 min read
Load More
AWARDS
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Biotech Bay
BridgeBio Pharma Announces Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
December 5, 2023
 · 
7 min read
Drug Development
BridgeBio Pharma Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
November 12, 2023
 · 
8 min read
Business
BridgeBio Pharma Reports Third Quarter 2023 Financial Results and Business Update
November 2, 2023
 · 
26 min read
Drug Development
BridgeBio presents detailed positive results from Phase 3 ATTRibute-CM study of acoramidis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) at European Society of Cardiology Congress 2023
August 27, 2023
 · 
11 min read
Drug Development
BridgeBio Pharma Presents Updated Six Month Results from its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia at the Endocrine Society (ENDO) 2023 Annual Conference
June 20, 2023
 · 
8 min read
Biotech Bay
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - June 13, 2023
June 13, 2023
 · 
1 min read
Biotech Bay
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 11, 2023
May 11, 2023
 · 
1 min read
Business
BridgeBio Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Business Update
February 23, 2023
 · 
23 min read
Biotech Bay
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - February 17, 2023
February 17, 2023
 · 
1 min read
Biotech Bay
BridgeBio Pharma to Participate in February and March Investor Events
February 8, 2023
 · 
1 min read
Load More